Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

311P - A global survey of the management of carcinomatous meningitis (CM) in breast cancer patients

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Breast Cancer;  Central Nervous System Malignancies

Presenters

Evangelia Razis

Citation

Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689

Authors

E. Razis1, A.G. Thulin2, R. Bartsch3, M.J. Escudero4, B. Linderholm2, D. Fumagali5, G. Rossi5, M. Gill Gill6, V. Müller7, C. Palmieri8, N. Kotecki9, I. Witzel10

Author affiliations

  • 1 3rd Dept Of Medical Oncology, Hygeia Hospital, 151 23 - Marousi/GR
  • 2 Oncology Department, Sahlgrenska University Hospital - Jubileumskliniken, 413 45 - Göteborg/SE
  • 3 Department Of Medicine 1, Division Of Oncology, Medizinische Universitaet Wien, 1090 - Vienna/AT
  • 4 Biostatistics, GEICAM-Spanish Breast Cancer Research Group, 28703 - San Sebastian de los Reyes/ES
  • 5 Research And Development, Breast International Group, 1000 - Bruxelles/BE
  • 6 Medical Oncology, Institut Català d'Oncologia. L'Hospitalet, 08908 - Barcelona/ES
  • 7 Department Of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE
  • 8 Department Of Molecular And Clinical Cancer Medicine, University of Liverpool/The Clatterbridge Cancer Centre NHS Foundation Trust, L693BX - Liverpool/GB
  • 9 Medical Oncology, Institut Jules Bordet, 1000 - Brussels/BE
  • 10 Department Of Gynecology, University Medical Center Hamburg, 20246 - Hamburg/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 311P

Background

Carcinomatous meningitis (CM) is a severe complication of breast cancer. BIG conducted a survey to describe the management of CM.

Methods

A questionnaire was created by the BMTF and distributed to all BIG groups, requesting one answer per site.

Results

245 sites responded from 55 groups, 121 in Europe, 9 in North America, 40 in Central and South America, 59 in Asia and 16 in Australia, 44% were university hospitals, 24% general hospitals with oncology units, 23% oncology centers and 9% private hospitals. The majority of sites (56%) report seeing <5 CM cases annually, more in oncology centers and teaching hospitals vs general and private hospitals [PC1] [SC2] (49% vs 34% p=0,0291). 60% report no increase in the number of cases of LM. 63% of sites actively investigate for CM in the presence of either symptoms or radiological evidence while 33% only in the presence of symptoms. A diagnosis of CM is based on CSF cytology and MRI findings in 71% of sites, while in 24% MRI findings alone suffice. 97% of sites treat CM, while 52% also refer all patients to palliative care. Treatment decisions are based upon systemic tumor burden, symptoms, CNS parenchymal disease, Performance Status, prognosis, and patient preference. Subtype of breast cancer influences management in only 64%. Intrathecal therapy is used in 42% of sites (Europe 50%, Latin America 48%, Australia 31%, Asia 29%, North America 22%), methotrexate being the drug of choice in 75%, infused through an Ommaya catheter and/or a lumbar puncture. 19% of sites use Ommaya catheters exclusively, while CSF flow is rarely checked. Radiotherapy is used for various indications in 88% of the centers. CSF cytology is not repeated after therapy in 47% of sites and follow up MRIs are used in 56%. 92% of sites do not have a national registry for patients with CNS metastases and of those that do, very few (25%) have one for CM. Most sites are interested in participating both in a registry as well as in clinical studies for CM with 62% favouring subtype specific studies.

Conclusions

This is the first study to map out the management of CM globally, showing a high degree of homogeneity in the clinical approach to this condition. There is significant interest in setting up a registry and conducting research.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Breast International Group (BIG).

Funding

Has not received any funding.

Disclosure

E. Razis: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Funding: Novartis; Financial Interests, Personal, Funding: Parexel; Financial Interests, Personal, Funding: Tesaro; Non-Financial Interests, Other, Honoraria: Bristol Myers Squibb; Other, Travel, Accommodations, Expenses: Genesis Pharmaceuticals; Other, Travel, Accommodations, Expenses: LEO Pharma; Other, Travel, Accommodations, Expenses: Roche; Other, Travel, Accommodations, Expenses: Genekor; Other, Travel, Accommodations, Expenses: Merck; Other, Travel, Accommodations, Expenses: Ipsen; Other, Travel, Accommodations, Expenses: Sanofi. R. Bartsch: Financial Interests, Advisory Role: Astra-Zeneca; Financial Interests, Advisory Role: Daiichi Sankyo; Financial Interests, Advisory Role: Eisai; Financial Interests, Advisory Role: Eli Lilly; Financial Interests, Advisory Role: MSD; Financial Interests, Advisory Role: Novartis; Financial Interests, Advisory Role: Pfizer; Financial Interests, Advisory Role: Pierre-Fabre; Financial Interests, Advisory Role: Puma; Financial Interests, Advisory Role: Roche; Financial Interests, Advisory Role: Seagen; Financial Interests, Other, Lecture Honoraria: AstraZeneca; Financial Interests, Other, Lecture Honoraria: Celgene; Financial Interests, Other, Lecture Honoraria: Eli Lilly; Financial Interests, Other, Lecture Honoraria: Novartis; Financial Interests, Other, Lecture Honoraria: Pfizer; Financial Interests, Other, Lecture Honoraria: Pierre-Fabre; Financial Interests, Other, Lecture Honoraria: Roche; Financial Interests, Other, Lecture Honoraria: Seagen; Financial Interests, Other, Research Support: Daiichi Sankyo; Financial Interests, Other, Research Support: MSD; Financial Interests, Other, Research Support: Novartis; Financial Interests, Other, Research Support: Roche. B. Linderholm: Financial Interests, Advisory Board: AstraZeneca; Financial Interests, Advisory Board: Pfizer; Financial Interests, Advisory Board: Merck; Financial Interests, Advisory Board: Eli Lilly; Financial Interests, Advisory Board: Pierre Fabre; Financial Interests, Advisory Board: Daiichi Sankyo/UCB Japan. D. Fumagali: Financial Interests, Funding: AstraZeneca; Financial Interests, Funding: Biovica; Financial Interests, Funding: GlaxoSmithKline; Financial Interests, Funding: Novartis; Financial Interests, Funding: Pfizer; Financial Interests, Funding: Roche/Genentech; Financial Interests, Funding: Tesaro; Financial Interests, Funding: Sanofi; Financial Interests, Funding: Servier. G. Rossi: Financial Interests, Funding: AstraZeneca; Financial Interests, Funding: Roche/Genentech; Financial Interests, Funding: Sanofi. V. Müller: Financial Interests, Other, grants and personal personal fees: Amgen; Financial Interests, Other, grants and personal personal fees: AstraZeneca; Financial Interests, Other, grants and personal personal fees: Daiichi Sankyo; Financial Interests, Other, grants and personal personal fees: Eisai; Financial Interests, Other, grants and personal personal fees: Pfizer; Financial Interests, Other, grants and personal personal fees: MSD; Financial Interests, Other, grants and personal personal fees: Novartis; Financial Interests, Other, grants and personal personal fees: Roche; Financial Interests, Other, grants and personal personal fees: Teva; Financial Interests, Other, grants and personal personal fees: Seattle Genetics; Financial Interests, Other, consultancy honoraria: Genomic Health; Financial Interests, Other, consultancy honoraria: Hexal; Financial Interests, Other, consultancy honoraria: Roche; Financial Interests, Other, consultancy honoraria: Pierre Fabre; Financial Interests, Other, consultancy honoraria: Amgen; Financial Interests, Other, consultancy honoraria: ClinSol; Financial Interests, Other, consultancy honoraria: Novartis; Financial Interests, Other, consultancy honoraria: MSD; Financial Interests, Other, consultancy honoraria: Daiichi Sankyo; Financial Interests, Other, consultancy honoraria: Eisai; Financial Interests, Other, consultancy honoraria: Lilly; Financial Interests, Other, consultancy honoraria: Tesaro; Financial Interests, Other, consultancy honoraria: Nektar; Financial Interests, Other, personal fees: Genomic Health; Financial Interests, Other, personal fees: Hexal; Financial Interests, Other, personal fees: Roche; Financial Interests, Other, personal fees: Pierre Fabre; Financial Interests, Other, personal fees: Amgen; Financial Interests, Other, personal fees: ClinSol; Financial Interests, Other, personal fees: Novartis; Financial Interests, Other, personal fees: MSD; Financial Interests, Other, personal fees: Daiichi Sankyo; Financial Interests, Other, personal fees: Eisai; Financial Interests, Other, personal fees: Lilly; Financial Interests, Other, personal fees: Tesaro; Financial Interests, Other, personal fees: Nektar. C. Palmieri: Financial Interests, Other, Honoraria: Pfizer; Financial Interests, Other, Honoraria: Roche; Financial Interests, Other, Honoraria: Eli Lilly; Financial Interests, Other, Honoraria: Novartis; Financial Interests, Other, Advisory board honoraria: Pfizer; Financial Interests, Other, Advisory board honoraria: Roche; Financial Interests, Other, Advisory board honoraria: Novartis; Financial Interests, Other, Advisory board honoraria: Eli Lilly; Financial Interests, Other, Advisory board honoraria: AstraZeneca; Financial Interests, Other, Conference sponsorship: Roche; Financial Interests, Other, Conference sponsorship: Daiichi Sankyo. I. Witzel: Financial Interests, Other, Speaker‘s Honoraria: Amgen; Financial Interests, Other, speaker‘s honoraria: MSD; Financial Interests, Other, speaker‘s honoraria: Novartis; Financial Interests, Other, speaker‘s honoraria: Pierre Fabre Pharme; Financial Interests, Other, speaker‘s honoraria: Pfizer; Financial Interests, Other, speaker‘s honoraria: Roche; Financial Interests, Other, speaker‘s honoraria: Sanofi-Aventis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.